• NanoViricides received FDA “Rare Pediatric Disease Drug” designation for NV-387 as a measles treatment, creating eligibility for a Priority Review Voucher.
• A voucher would be awarded only if an NDA is approved; it can be used to speed another review or sold, with recent sales cited at USD 195 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606290830ACCESSWRNAPR_____1183677) on June 29, 2026, and is solely responsible for the information contained therein.